Journal: Frontiers in Oncology

Article Title: Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis

doi: 10.3389/fonc.2021.628138

Figure Lengend Snippet: Examples of clinical trials of Immune targets in breast cancer immunotherapy.

Article Snippet: 4-1BB agonist , PF-05082566 (Utolimumab) , Pfizer , + Trastuzumab – Emtansine , I , NCT03364348.

Techniques:

Journal: Journal for Immunotherapy of Cancer

Article Title: 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 + CD8 T cells from primary and metastatic sites of epithelial ovarian cancers

doi: 10.1136/jitc-2020-001650

Figure Lengend Snippet: 4-1BB agonistic antibodies enhanced the function of exhausted CD8 tumor-infiltrating lymphocytes (TILs). (A) Efficacy of 4-1BB co-stimulation with anti-CD3 stimulation in terms of CD8 TIL proliferation. In the presence of anti-CD3 antibodies, we analyzed the frequency of CTV low CD8 TILs (proliferated CD8 TILs) in the presence of isotype or anti-4-1BB agonistic antibodies. Representative flow cytometry plots are shown on the left, and data are presented as the stimulation index. (B–C) Effects of 4-1BB co-stimulation were also assessed in terms of cytokine production, representing functional capacity. Interferon (IFN)-γ and tumor necrosis factor (TNF)-α production in CD8 TILs was measured by intracellular staining. Representative flow cytometry plots are shown on the left, and data are presented as the relative ratio to the isotype-treated group, separately for cells from the ovary (B) and metastatic sites (C). *P<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Article Snippet: Then those labeled cells were stimulated with 1 ng/mL anti-CD3 antibody (OKT-3; eBioscience), and with or without 5 µg/mL anti-PD-1 blocking antibody (EH12.2H7; BioLegend, San Diego, California, USA) and 10 µg/mL anti-4-1BB agonistic antibody (provided by ABL Bio, Seongnam, Korea).

Techniques: Flow Cytometry, Functional Assay, Staining

Journal: Journal for Immunotherapy of Cancer

Article Title: 4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 + CD8 T cells from primary and metastatic sites of epithelial ovarian cancers

doi: 10.1136/jitc-2020-001650

Figure Lengend Snippet: 4-1BB co-stimulation further enhances antiprogrammed cell death protein 1 (anti-PD-1)-mediated reinvigoration of exhausted CD8 tumor-infiltrating lymphocytes (TILs) from the ovary and metastatic sites. (A) In the presence of anti-CD3 antibodies, we analyzed the frequency of CTV low CD8 TILs (proliferated CD8 TILs) in the presence of isotype or anti-PD-1 blocking antibodies, or a combination of anti-PD-1 blocking antibodies and anti-4-1BB agonistic antibodies. Representative flow cytometry plots are shown to the left, and data are presented as the stimulation index. (B–C) We evaluated changes of the functional capacities of CD8 TILs after stimulation with antibodies by intracellular staining of cytokines (interferon (IFN)-γ and tumor necrosis factor (TNF)-α). We compared three different treatment groups: isotype-treated, anti-PD-1 blocking antibodies-treated and combined treatment with anti-PD-1 blocking antibodies and anti-4-1BB agonistic antibodies. Representative flow cytometry plots are shown to the left, and data are presented as the relative ratio to the isotype-treated group, separately for the ovary (B) and metastatic sites (C). *P<0.05; **p<0.01; ***p<0.001; ****p<0.0001.

Article Snippet: Then those labeled cells were stimulated with 1 ng/mL anti-CD3 antibody (OKT-3; eBioscience), and with or without 5 µg/mL anti-PD-1 blocking antibody (EH12.2H7; BioLegend, San Diego, California, USA) and 10 µg/mL anti-4-1BB agonistic antibody (provided by ABL Bio, Seongnam, Korea).

Techniques: Blocking Assay, Flow Cytometry, Functional Assay, Staining